Global Fertility Treatments Market

Fertility treatment is a medical procedure intended to increase the chances of conceiving a child. These services are used to increase the chances of bearing a child. The main types of services in fertility services are fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor. Donor eggs are collected and immediately ertilized with the male partner’s sperm in a fresh donor egg IVF cycle, with the developing fresh embryos being delivered to the recipient. The leftover embryos can be preserved and used in future frozen embryo transfers. The different procedures include assisted reproductive technology (ART), in-vitro fertilization, artificial insemination and is used by both male, female. The fertility services market research report is one of a series of new reports from The Business Research Company that provides fertility services market statistics, including fertility services industry global market size, regional shares, competitors with a fertility services market share, detailed fertility services market segments, market trends and opportunities, and any further data you may need to thrive in the fertility services industry. This fertility services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility services market size will grow from $47.17 billion in 2022 to $54.12 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global fertility services market size is expected to grow to $90.14 billion in 2027 at a CAGR of 13.6%. Growing infertility rates are anticipated to boost the demand for fertility services during the forecast period. Various social and environment-related factors such as lifestyle changes including obesity, stress or depression, and high consumption of alcohol contribute to a surge in infertility rates, thereby generating the high requirement for fertility services. For example, in 2020, according to NPR, a US-based non-profit media organization, there were 4% fewer babies born in the United States in 2020 than in 2019. The preliminary figures showed that the overall fertility rate hit yet another record low, at 55.8 births per 1,000 women aged 15 to 44. Thus, growing infertility rates will drive the demand for fertility services. The high cost of fertility services is expected to limit the growth of the fertility services market. The cost of in-vitro fertilization (IVF) primarily depends on infertility workup and varies from person to person. For instance, the average cost of one in-vitro fertilization (IVF) cycle is $12,000. The range of cost involved in one IVF cycle can be between $10,000 and $15,000, which excludes the cost of medication which may be as low as $1,500 or as high as $3,000 per cycle. The IVF cost is continuously rising attributing to modern diagnostic tests and various treatment methods such as hysteroscopy, IUI, and laparoscopy being used to facilitate and aid infertility treatment cost. Therefore, the high cost of fertility treatment is to act as a major challenge for the development of the fertility services market. Companies in the fertility services market have witnessed significant growth in the number of research collaborations as well as research funding approvals. Key companies operating in the market are projected to increase their R&D expenditure to introduce new advanced techniques and drugs used for fertility treatments. For instance, in October 2022, Maven Clinic, a US-based company specializing in telemedicine-based virtual clinic for women's and family health, collaborated with Indira IVF. The collaboration aimed at providing access to Maven members in India to Indira IVF's high-quality clinical care, other perks, and the best virtual family-building care available through the Maven platform. Indira IVF is an India-based infertility speciality clinic chain. Furthermore, in February 2021, CooperSurgical, a US-based company specializing in women’s health care solutions, collaborated with Virtus Health. The collaboration aimed at emphasizing on digitalization, cryogenics, and reproductive genetics, the cooperation will lead initiatives to assist patients' fertility journeys, including those who require egg, sperm, or embryo donations. Virtus Health is an Australia-based company specializing in fertility services. In December 2021, CooperCompanies, a US-based company specializing in women’s healthcare solutions, acquired Generate Life Sciences for $1.6 billion. Through this acquisition, CooperSurgical offers an even stronger selection of fertility centres and OB/GYNs. Generate Life Sciences is a US-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage. Major players in the fertility services market are Merck KGaA, Care Fertility, INVO Bioscience, Vitrolife, Monash IVF Group, Carolinas Fertility Institute, IntegraMed, Inc., New Hope Fertility Centre and Apollo Hospitals Enterprise Ltd. Western Europe was the largest region in the fertility services market in 2022. North America was the second largest region in global fertility services market. The regions covered in the global fertility services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The fertility services market includes revenues earned by entities by providing artificial insemination, and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global fertility services market is segmented - 1) By Procedure: Assisted Reproductive Technology (ART), In-Vitro Fertilization, Artificial Insemination 2) By Service: Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, Frozen Donor 3) By Application: Male, Female

Assisted reproductive technology is based on the surgical removal of eggs from women’s ovaries and then fusing them with men’s sperm in the laboratory to create embryos. These embryos are then inserted back into the woman’s body. ART uses donor eggs, donor sperm, or previously stored frozen embryos. Assisted reproductive technology (ART) is used for the treatment of infertility in either eggs or embryos. The main types of assisted reproductive technology are in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others. In-vitro fertilisation (IVF) is a complicated operation that involves collecting eggs and fertilising them with sperm in a lab to create embryos. These embryos are subsequently implanted into women's reproductive organs. The different procedure types include fresh non-donor, fresh donor, frozen donor, frozen non donor, embryo or egg banking and is used in hospitals, fertility clinics, others. The assisted reproductive technology (ART) market research report is one of a series of new reports from The Business Research Company that provides assisted reproductive technology (ART) market statistics, including assisted reproductive technology (ART) industry global market size, regional shares, competitors with a assisted reproductive technology (ART) market share, detailed assisted reproductive technology (ART) market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology (ART) industry. This assisted reproductive technology (ART) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global assisted reproductive technology market size grew from $31.4 billion in 2022 to $37.56 billion in 2023 at a compound annual growth rate (CAGR) of 19.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The assisted reproductive technology market size is expected to grow to $75.64 billion in 2027 at a CAGR of 19.1%. The rising number of infertility cases is expected to foster the assisted reproductive technology market in the coming years. Infertility is defined as the failure to become pregnant after a year of frequent and unprotected intercourse. Infertility affects both men and women, and is typically diagnosed by the inability to conceive. Infertility is treated using assisted reproductive technology (ART). Fertility therapies that work with both a woman's egg and a man's sperm are included in this. For instance, according to the UCLA Health, a US based health system, in 2020 around 15% of couples in the world have trouble in conceiving. Infertile couples are increasingly turning to assisted reproductive technology (ART), which is growing at a rate of 5% to 10% every year. Therefore, the rising number of infertility cases drives the growth of the assisted reproductive technology market. Technological advancements is a key trend gaining the popularity in the assisted reproductive technology market. Major companies operating in the assisted reproductive technology are focused on developing technological solutions to strengthen their position. For instance, in November 2020, NIPD Genetics, a Cyprus based biotechnology company launched Amfira PGT based on Target Capture Enrichment Technology. Amfira PGT is a preimplantation genetic test which can be employed during fertility treatment to improve the odds of becoming pregnant and giving birth to a healthy child. Amfira PGT can be used in In Vitro Fertilization (IVF) cycles to determine whether embryos are chromosomally normal (euploid) and have the best chance of culminating in a safe pregnancy and birth. In August 2021, Virtus Health Limited, an Australia-based company offering assisted reproductive technology acquired Adora Fertility and three-day hospitals from Healius Limited for $45.0 million. This acquisition will help Virtus health to strengthen its portfolio for in-vitro fertilization (IVF). Adora Fertility is an Australia-based company that provide assisted reproductive technology (ART) including IVF (In-vitro fertilisation) and ICSI (Intracytoplasmic Sperm Injection). Major players in the assisted reproductive technology market are Cooper Surgical Inc., Ferring B.V., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific, Boston Science Corporation, Anecova, Carolinas Fertility Institute, Microm Ltd. Europe was the largest region in the assisted reproductive technology market in 2022. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology (ART) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the assisted reproductive technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global assisted reproductive technology market is segmented - 1) By Diagnosis: Ovulation Testing, Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing 2) By Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking 3) By End-User: Hospitals, Fertility Clinics, Other End-Users

The femtech are technology to support women's health which uses software, diagnostics, products, and services to cater to female biological needs. The main types of femitech are devices, software, services, and others. Devices refer to a wide range of tools and products that are used for women's health improvement, consisting of wearable devices, treatment devices, and others. Software is used in female technological products for women's wellness and women's healthcare. Services include medical services that are used in women's healthcare, which are comprised of therapy services used in wellness and healthcare. The various end-users of femtech include direct-to-consumer, hospitals, fertility clinics, surgical centers, and diagnostic centres for applications such as reproductive health, pregnancy and nursing care, pelvic and uterine healthcare, general healthcare and wellness, and others. The femtech market research report is one of a series of new reports from The Business Research Company that provides femtech market statistics, including femtech industry global market size, regional shares, competitors with a femtech market share, detailed femtech market segments, market trends and opportunities, and any further data you may need to thrive in the femtech industry. This femtech market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global femtech market size grew from $32.44 billion in 2022 to $37.39 billion in 2023 at a compound annual growth rate (CAGR) of 15.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The femtech market size is expected to grow to $68.9 billion in 2027 at a CAGR of 16.5%. The rise of digital healthcare is expected to propel the growth of the femtech market. Digital health care technologies use connectivity, software, and sensors for health care and related uses. For instance, in October 2020, according to the Center for Disease Control and Prevention’s (CDC) data from four of the largest U.S. telehealth providers, during the first quarter of the year 2020, the number of telehealth visits increased by 50%, compared with the same period in the year 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. Therefore, the favourable consumer perception and tangible investments in digital health are expected to propel the growth of the femtech market. Advanced technology products are a key trend gaining popularity in the femtech market. Companies are focusing on developing products that generate accurate results and also reduce the handling time of products. For instance, in 2021, Lia, a US-based company, launched the world’s first flushable and biodegradable pregnancy test device made from plant fibres and is 100% plastic-free, which can biodegrade in just ten weeks. In July 2022, FemTec Health, a US-based health and beauty sciences company acquired Ava Women for an undisclosed amount. Through this acquisition, FemTech Health aims to expand its product portfolio in reproductive health solutions. Ava Women is a Switzerland-based digital diagnostics and therapeutics company specializing in women’s reproductive health.   Major players in the femtech market are Athena Feminine Technologies, Sustain Natural, Sera Prognostics, HeraMED, iSona Health, Totohealth, Minvera, Nuvo, Elvie, Biowink, and Lia North America was the largest region in the femtech market in 2022. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the femtech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The femtech market includes revenues earned by entities by providing period tracker, fertility tracking and solutions, menstruation products, prenatal and postnatal care products, and reproduction healthcare products.   The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global femtech market is segmented - 1) By Type: Devices, Software, Services, Other Types 2) By End Use: Direct-To-Consumer, Hospitals, Fertility Clinics, Surgical Centers, Diagnostic Centers 3) By Application: Reproductive Health, Pregnancy and Nursing Care, Pelvic and Uterine Healthcare, General Healthcare and Wellness, Other Applications

IVF is a process of fertilization where an egg is combined with sperm outside the body, in vitro ("in glass”). In vitro fertilization (IVF) is a sophisticated set of treatments intended to improve fertility, avoid genetic issues, and aid in child conception. It is used to address infertility. The main types of cycles in IVF services markets are fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. When an IVF cycle is completed utilizing eggs and embryos that have never been frozen, it is referred to as a fresh IVF cycle. After the eggs are extracted, they are fertilized in the lab with semen. The different service providers include fertility clinics, hospitals, surgical centres, clinical research institutes and is used in various sectors such as fertility clinics, hospitals, and other settings. The IVF services market research report is one of a series of new reports from The Business Research Company that provides IVF services market statistics, including IVF services industry global market size, regional shares, competitors with a IVF services market share, detailed IVF services market segments, market trends and opportunities, and any further data you may need to thrive in the IVF services industry. This IVF services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ivf services market size will grow from $15.38 billion in 2022 to $17.13 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ivf services market size is expected to grow to $25.27 billion in 2027 at a CAGR of 10.2%. The rising infertility rate contributed to the growth of the in vitro fertilization (IVF) services market. Infertility is known as the inability to conceive within 12 months. According to the US Department of Health and Human Services, around 12 to 13 couples in 100 have a problem in conceiving. Moreover, according to the Indian Journal of Community Medicine, 15 to 20 million infertility cases are in India alone. The rising infertility rate made people resort to IVF services contributing to the growth of the market. The high cost of IVF services limits the in-vitro fertilization (IVF) services market. For instance, the cost of a basic IVF package ranges from $4,700 to $20,000, and the average price in the USA is around $12,000. The total cost of a single IVF cycle can range between $8,000 to $30,000. According to FertilityIQ, the cost of IVF services was around $22,000. In emerging economies like India, the cost of IVF services ranges from INR 70,000 to INR 300,000. The high cost of IVF services makes it unavailable to low- and middle-income populations negatively affecting the IVF services' market growth. Platelet-rich plasma (PRP) is the latest technique increasingly used for improving IVF success rate in patients with recurrent implantation failures. PRP is used alongside fertility treatments like IVF to improve egg quality, uterine lining thickness and endometrial receptivity, and the treatment is primarily for recurrent implantation failure over multiple IVF cycles. According to an article published by the Journal of Assisted Reproduction and Genetics, women treated with PRP experienced a significant improvement in Follicle-Stimulating Hormone (FSH), Anti-Müllerian Hormone (AMH), and Antral Follicle Count (AFC) and help improve fertility. In December 2020, Fresenius Helios, a Germany-based healthcare company acquired Eugin Group for $ 195.98 million (€160 million). The acquisition expands Fresenius Helios's global network of fertility clinics, providing tremendous growth and consolidation potential. Eugin Group is a Spain-based company that provides IVF services. Major players in the IVF services market are Ambroise Par Group, amedes MVZ Köln GmbH, AMP Centre St Roch, AVA Clinic Scanfert, Bangkok IVF center, Betamedics, Bloom Fertility and Healthcare, Bourn Hall Fertility Centre, Biofertility Centre and Chelsea and Westminster Hospital (Assisted Conception Unit). Western Europe was the largest region in the IVF services market in 2022. North America was the second largest region in global IVF services market. The regions covered in the global IVF services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the IVF services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The IVF services market includes revenues earned by entities by providing services such as conventional insemination services, and intracytoplasmic sperm injection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global IVF services market is segmented - 1) By Cycle Type: Fresh IVF Cycles(Non-donor), Thawed IVF Cycles(Non-donor), Donor Egg IVF Cycles 2) By Service Provider: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By End User: Fertility Clinics, Hospitals & Other Settings

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Medical tourism is the process of travelling to another country solely for the reasons of medical treatment. It is useful for people living in countries where appropriate medical facilities are not available. The main types of medical tourism are domestic and international. Domestic health or medical tourism is when a person travels from his or her regular place of residence to another inside the state in order to receive better medical treatment or because the therapy available in his or her usual place of residence is too expensive. The different treatment types include cosmetic treatment, dental treatment, cardiovascular treatment, orthopedics treatment, bariatric treatment, fertility treatment, opthalmic treatment, others and involves various service providers such as public, private. The several healthcare services include medical treatment, wellness, alternative treatment. The medical tourism market research report is one of a series of new reports from The Business Research Company that provides medical tourism market statistics, including medical tourism industry global market size, regional shares, competitors with a medical tourism market share, detailed medical tourism market segments, market trends and opportunities, and any further data you may need to thrive in the medical tourism industry. This medical tourism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical tourism market size will grow from $35.77 billion in 2022 to $39.95 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global medical tourism market size is expected to grow to $59.67 billion in 2027 at a CAGR of 10.5%. High healthcare cost in developed countries is driving growth in the medical tourism market as developing countries are able to provide cheaper treatment. Patients usually travel to developing countries with quality healthcare infrastructure and low healthcare costs. According to a study conducted by the Centres for Disease Control and Prevention, approximately 0.75 -1.6 million people from the USA travel out of the country for medical care to avoid high treatment cost. For instance, a hip replacement surgery in the USA costs approximately $39,299 while the same surgery in India, Costa Rica or other developing countries would cost between $7000 and $15,000 including logistics. The coronavirus disease (COVID-19) outbreak is to act as a major restraint for the growth of the medical tourism industry during 2020 and 2021. According to the World Health Organization’s report, 213 countries are affected by the COVID-19 outbreak including countries with a high number of medical tourists such as the USA, China, Japan, and South Korea. The government of various countries has banned travellers from affected countries, barred flights to certain countries, and changed the visa requirements. The American Centres for Disease Control and Prevention (CDC) predicted that the situation could last into 2021 and is likely to impact the medical tourism industry significantly. Therefore, the coronavirus outbreak and travel bans are expected to restrict the growth of the medical tourism industry in the near future. Patients traveling across countries for medical treatment are increasingly using electronic health records to store information related to health in digital format. An electronic health record is the systematic collection of patient health and medical examination reports stored electronically. These health records can be accessed instantly and securely by authorized users. Electronic health records eliminate the need to carry heavy medical records for patients travelling long distances for treatment. Some of the major electronic health records software include eClinicalWorks, Allscripts, Cerner. In September 2020, IHH Healthcare, a Malaysian–Singaporean private healthcare group focused on upmarket health services acquired Prince Court Medical Centre for $0.25 billion. Through this acquisition, Prince Court Medical Centre will complement IHH's cluster strategy of having specialized tertiary hospitals in Kuala Lumpur. Prince Court Medical Centre is a private healthcare facility located in the heart of Kuala Lumpur, Malaysia. Major players in the medical tourism market are Apollo Hospital Enterprise Limited, Prince Court Medical Centre, Bumrungrad International Hospital, KPJ Healthcare Berhad, Fortis Health Ltd., Raffles Medical Group, Bangkok Hospital Medical Centre, Samitivej PCL., Min-Sheng General Hospital and Asian Heart Institute. North America was the largest region in the medical tourism market in 2022. Western Europe was the second largest region in the global medical tourism market. The regions covered in the global medical tourism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical tourism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The medical tourism market includes revenues earned by entites by providing inbound medical tourism services, and outbound medical tourism services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global medical tourism market is segmented - 1) By Treatment Type: Cosmetic Treatment, Dental Treatment, Cardiovascular Treatment, Orthopedics Treatment, Bariatric Treatment, Fertility Treatment, Opthalmic Treatment, Other Treatments 2) By Type: Domestic, International 3) By Healthcare Service: Medical Treatment, Wellness, Alternative Treatment 4) By Service Providers: Public, Private

Fertility drugs refer to a term used to describe medications that cause your body to release hormones that regulate or prompt ovulation, or the release of an egg from your ovary. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered orally, intravenously, subcutaneously, and intramuscularly to male and female patients. Subcutaneous administration refers to the process of injecting the drugs into the fatty tissue just beneath the skin. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The fertility drugs market research report is one of a series of new reports from The Business Research Company that provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for infertility market size will grow from $2.93 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for infertility market size is expected to grow to $3.30 billion in 2027 at a CAGR of 2.1%. The growth of the market for fertility drugs is driven by the increasing rates of infertility across the globe. Infertility is the inability to conceive after trying for 12 consecutive months. Fertility drugs are widely used to treat infertility in both men and women. The rising rates of infertility are attributed to physiological problems, hormone problems, and lifestyle or environmental factors. To treat infertility problems in women, fertility drugs are used to regulate their ovulation cycles, which affects the sale of these drugs. For instance, in September 2020, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age will struggle with infertility, which will also have an effect on their families and communities. Worldwide, it is estimated that 48 million couples and 186 million people struggle with infertility. Hence, the rising cases of infertility across the globe are increasing the demand for fertility drugs, resulting in the growth of the fertility drug market. The side effects caused due to fertility drugs restricted the growth of the fertility drugs market. Fertility drugs can result in permanent as well as temporary side effects. Temporary side effects include bloating, headache, breast tenderness, upset stomach, hot flashes, and mood swings whereas the permanent side effects include multiple pregnancies, and ovarian hyperstimulation syndrome (OHSS). OHSS is a condition where the ovaries enlarge with fluids and may become life-threatening if left untreated. For instance, the intake of Clomid (clomiphene citrate), a fertility drug for women, can result in OHSS along with abnormal vaginal/uterine bleeding, breast tenderness or discomfort, headache, nausea, vomiting, diarrhea, flushing, blurred vision, or other visual disturbances. The fear of potential side effects of fertility drugs restricts the growth of the fertility drugs market. The companies in the fertility drugs market are focusing on the launch of self- administration fertility solutions for advanced infertility treatment. The self- administration fertility solution makes it easier and less painful for women to self-administer daily injections. For example, in August 2021, Merck Specialities, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. This launch aims to fulfill unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. The Pergoveris Pen is a combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment. In January 2020, Evotec SE, a Germany-based pharmaceutical company specialising in drug discovery and development, announced strategic partnerships with Bayer AG, a pharmaceutical and biotechnology company pioneering in the discovery, development, manufacturing, and commercialization of drugs. Under this collaboration, to develop a new cure and multiple clinical candidates for the treatment of polycystic ovary syndrome together, both businesses will offer drug targets and a wide array of high-quality technological platforms. Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma, LIVZON, Abbott, MSD, Sanofi S.A., Eli Lilly and Co., Serono, Inc., Novogyne Pharmaceuticals, and Takeda Pharmaceutical co. ltd. North America was the largest region in the fertility drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for infertility market during the forecast period. The regions covered in the global fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility drugs market is segmented - 1) By Gender: Male, Female 2) By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular 3) By Type Of Drug: Prescription Fertility Drugs, Over-The-Counter Fertility drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs